Article
Pharmacology & Pharmacy
Ranita Kirubakaran, David W. Uster, Stefanie Hennig, Jane E. Carland, Richard O. Day, Sebastian G. Wicha, Sophie L. Stocker
Summary: A population pharmacokinetic model that considers the tacrolimus-azole antifungal interaction was developed for guiding tacrolimus dosing in heart transplant recipients.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Ranita Kirubakaran, Stefanie Hennig, Ben Maslen, Richard O. Day, Jane E. Carland, Sophie L. Stocker
Summary: This study evaluated the predictive performances of 17 population pharmacokinetic models of tacrolimus in adult heart transplant recipients, showing that these models were unable to adequately describe the pharmacokinetics of tacrolimus in this specific population. Further research is needed to better understand tacrolimus pharmacokinetics in heart transplant recipients.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Xipei Wang, Yijin Wu, Jinsong Huang, Songgui Shan, Mingjie Mai, Jiade Zhu, Min Yang, Dewei Shang, Zheng Wu, Jinhua Lan, Shilong Zhong, Min Wu
Summary: This study aimed to establish a strategy for estimating the area under the curve of mycophenolic acid (MPA) in heart transplant recipients and identify covariates affecting MPA pharmacokinetics. A PPK model was developed with three covariates, demonstrating the impact of proton pump inhibitors and estimated glomerular filtration rate on MPA exposure. Additionally, a linear equation using four time points was proposed as an alternative method for estimating MPA AUC(0-12h).
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Kanyaporn Khamlek, Virunya Komenkul, Tatta Sriboonruang, Thitima Wattanavijitkul
Summary: This study reviewed the population pharmacokinetic models of tacrolimus in paediatric patients and identified factors such as body weight, CYP3A5 genotype, days post-transplant, and haematocrit that influence tacrolimus pharmacokinetics in this population. However, only a small percentage of the studies assessed the external validity of the models. Further research is needed to determine the relationship between pharmacogenetics and tacrolimus pharmacodynamics in paediatric patients and confirm the applicability of nonlinear kinetics in this population.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Review
Medicine, Research & Experimental
Milosz Miedziaszczyk, Ilona Idasiak-Piechocka
Summary: Tacrolimus and omeprazole are commonly used drugs in kidney transplant patients. However, simultaneous administration may lead to drug interactions, affecting the pharmacokinetics of tacrolimus and potentially causing adverse reactions. It is important to address these interactions and find appropriate solutions.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Xiao-Jun Cai, Yan Chen, Xiao-Shan Zhang, Yu-Zhen Wang, Wen-Bo Zhou, Chun-Hong Zhang, Bo Wu, Hui-Zhu Song, Hang Yang, Xu-Ben Yu
Summary: This study investigated the population pharmacokinetics of polymyxin B in lung transplant recipients and found that renal function significantly affected the clearance of polymyxin B, suggesting the need for dosage adjustment in patients with renal impairments.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yan Jing, Ying Kong, Xiongjun Hou, Hong Liu, Qun Fu, Zheng Jiao, Hongwei Peng, Xiaohua Wei
Summary: The study assessed the impact of TAC+WZC co-administration and genetic polymorphism on the pharmacokinetics of TAC, proposing a dosing guideline for individualized TAC dosing.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2021)
Article
Surgery
Pan Chen, Rui Dai, Youjun She, Qian Fu, Min Huang, Xiao Chen, Changxi Wang
Summary: This study evaluated the pharmacokinetic interaction between Wuzhi and tacrolimus (TAC) and identified CYP3A5 genotypes, baseline C0/D, and hematocrit (Hct) as determinants of this interaction.
CLINICAL TRANSPLANTATION
(2022)
Article
Pharmacology & Pharmacy
Lekshmy Srinivas, Noble Gracious, Radhakrishnan R. Nair
Summary: Tacrolimus is an immunosuppressant used in solid organ transplantation. This study in South Indian renal transplant recipients investigated the effects of gene polymorphisms on tacrolimus concentrations and adverse effects. The findings suggest that genotype-guided initial dosing of tacrolimus can help achieve optimal drug levels and prevent adverse effects.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Adrien Paschier, Alexandre Destere, Caroline Monchaud, Marc Labriffe, Pierre Marquet, Jean-Baptiste Woillard
Summary: This study developed a population pharmacokinetic (PK) model for tacrolimus in heart transplant patients and built a maximum a posteriori Bayesian estimator (MAP-BE) based on a limited sampling strategy (LSS) to estimate the area under the curve (AUC) and trough concentration (C0). The results showed that the MAP-BE based on LSS had a small bias and imprecision compared to the reference AUC calculated using the trapezoidal rule. The probabilities of target attainment (PTAs) based on AUC or C0 allowed for new recommendations for starting doses in CYP3A5 nonexpressors and expressors.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Junjun Mao, Xiaoyan Qiu, Weiwei Qin, Luyang Xu, Ming Zhang, Mingkang Zhong
Summary: The pharmacokinetic properties of cyclosporine in renal transplant recipients are influenced by patient-specific factors and change over time. Factors such as body size, hematocrit level, prednisolone dose, and genetic haplotypes may contribute to the variability in cyclosporine exposure. Tailoring cyclosporine dosing based on these factors at different postoperative periods could optimize therapy outcomes.
PHARMACEUTICAL RESEARCH
(2021)
Article
Medical Laboratory Technology
Pierre Marquet, Florine Cros, Ludovic Micallef, Evelyne Jacqz-Aigrain, Jean-Baptiste Woillard, Caroline Monchaud, Franck Saint-Marcoux, Jean Debord
Summary: By analyzing the ISBA database, it was found that there is significant between-patient variability in tacrolimus AUC, but moderate within-patient variability. The recommended dose from ISBA can significantly reduce underexposure and overexposure, leading to a narrower AUC distribution within the target range.
THERAPEUTIC DRUG MONITORING
(2021)
Review
Pharmacology & Pharmacy
Da-Hoon Lee, Hana Lee, Ha-Young Yoon, Jeong Yee, Hye-Sun Gwak
Summary: There is a correlation between the POR*28 genotype and the pharmacokinetics of TAC in early post-transplantation period in adult renal transplant recipients. Recipients with the POR*28 allele have lower standardized trough concentrations of TAC.
Article
Medical Laboratory Technology
Amy L. Pasternak, Jeong M. Park, Manjunath P. Pai
Summary: Three published popPK models for tacrolimus dosing in pediatric kidney and heart transplant recipients were compared, and it was found that weight-based dosing underestimates the dose requirements and a separate model is needed for heart transplant patients. The genotype-guided strategy based on the Chen et al model provided the best estimates for kidney transplant patients.
THERAPEUTIC DRUG MONITORING
(2023)
Article
Pharmacology & Pharmacy
Xiao-Lin Liu, Yan-Ping Guan, Ying Wang, Ke Huang, Fu-Lin Jiang, Jian Wang, Qi-Hong Yu, Kai-Feng Qiu, Min Huang, Jun-Yan Wu, Dun-Hua Zhou, Guo-Ping Zhong, Xiao-Xia Yu
Summary: This study developed a population pharmacokinetic (PopPK) model for tacrolimus in pediatric HSCT patients and identified significant covariates that influence its pharmacokinetics. The study also provided model-guided dosage regimens for pediatric patients. Initial dosage optimization for intravenous and oral administration of tacrolimus was recommended as 0.025 and 0.1 mg kg(-1) d(-1) (q12h), respectively.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Benedicte Franck, Sylvain Dulaurent, Souleiman El Balkhi, Caroline Monchaud, Nicolas Picard, Sylvain Couderc, Pierre Marquet, Franck Saint-Marcoux, Jean-Baptiste Woillard
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2019)
Review
Medicine, Research & Experimental
Joseph Berthier, Helene Arnion, Franck Saint-Marcoux, Nicolas Picard
Article
Pharmacology & Pharmacy
Chantal Barin-Le Guellec, Nicolas Picard, Hugo Alarcan, Melody Barreau, Laurent Becquemont, Sylvie Quaranta, Jean-Christophe Boyer, Marie-Anne Loriot
Article
Surgery
Yannick Le Meur, Lionel Badet, Marie Essig, Antoine Thierry, Matthias Buchler, Sarah Drouin, Charles Deruelle, Emmanuel Morelon, Francis Pesteil, Pierre-Olivier Delpech, Jean-Michel Boutin, Felix Renard, Benoit Barrou
AMERICAN JOURNAL OF TRANSPLANTATION
(2020)
Article
Immunology
Hugoline Boulay, Emmanuel Oger, Diego Cantarovich, Philippe Gatault, Antoine Thierry, Yannick Le Meur, Agnes Duveau, Cecile Vigneau, Nolwenn Lorcy
Summary: The study results indicate that the absence of prophylaxis did not appear to have a deleterious effect on CMV diseases among CMV R+ recipients receiving non-depleting induction.
TRANSPLANT INFECTIOUS DISEASE
(2021)
Article
Pharmacology & Pharmacy
Jean-Baptiste Woillard, Marc Labriffe, Aurelie Premaud, Pierre Marquet
Summary: This study demonstrates the successful estimation of tacrolimus AUC through machine learning methods despite limited databases. Xgboost model performs excellently in estimating tacrolimus inter-dose AUC and shows comparable results to MAP-BE.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Surgery
Hannah Kaminski, Nassim Kamar, Olivier Thaunat, Nicolas Bouvier, Sophie Caillard, Isabelle Garrigue, Dany Anglicheau, Jean-Philippe Rerolle, Yannick Le Meur, Antoine Durrbach, Thomas Bachelet, Helene Savel, Roxane Coueron, Jonathan Visentin, Arnaud Del Bello, Isabelle Pellegrin, Julie Dechanet-Merville, Pierre Merville, Rodolphe Thiebaut, Lionel Couzi
Summary: This study found that everolimus can decrease the incidence of CMV DNAemia and disease in CMV seropositive solid organ transplant recipients.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Article
Engineering, Biomedical
Yannick Le Meur, Eric Delpy, Felix Renard, Thierry Hauet, Lionel Badet, Jean Philippe Rerolle, Antoine Thierry, Matthias Buchler, Franck Zal, Benoit Barrou
Summary: The study evaluated the safety and efficacy of using HEMO(2)life (R) as an additive to preservation solution in renal transplantation, showing lower DGF rates and better renal function in the HEMO(2)life (R) group. Analysis using Kaplan-Meier estimate curves, Cox model, and Bootstrap confirmed the advantages of the HEMO(2)life (R) group.
Article
Microbiology
Claire V. Hoffmann, Gilles Nevez, Marie-Christine Moal, Dorothee Quinio, Nathan Le Nan, Nicolas Papon, Jean-Philippe Bouchara, Yannick Le Meur, Solene Le Gal
Summary: MPA may exert selective pressure on specific P. jirovecii strains circulating in SOT recipients.
Article
Pharmacology & Pharmacy
Tom M. Nanga, Jean-Baptiste Woillard, Annick Rousseau, Pierre Marquet, Aurelie Premaud
Summary: In this study, a precise and accurate Bayesian estimator was developed to estimate the therapeutic effects of mycophenolate mofetil in autoimmune hepatitis patients. This estimator can help improve the therapeutic management of these patients.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Alexandre Destere, Pierre Marquet, Charlotte Salmon Gandonniere, Anders Asberg, Veronique Loustaud-Ratti, Paul Carrier, Stephan Ehrmann, Chantal Barin-Le Guellec, Aurelie Premaud, Jean-Baptiste Woillard
Summary: This study investigates the use of a hybrid machine learning/population pharmacokinetic approach to improve individual iohexol clearance estimation. The results show that machine learning algorithms can correct the limited sampling-based MAP-BE clearance estimates, leading to a decrease in estimation error.
CLINICAL PHARMACOKINETICS
(2022)
Article
Surgery
Marie Courbebaisse, Aurelie Bourmaud, Jean-Claude Souberbielle, Rebecca Sberro-Soussan, Valerie Moal, Yannick Le Meur, Nassim Kamar, Laetitia Albano, Antoine Thierry, Jacques Dantal, Clement Danthu, Karine Moreau, Emmanuel Morelon, Anne-Elisabeth Heng, Dominique Bertrand, Nadia Arzouk, Peggy Perrin, Marie-Pascale Morin, Philippe Rieu, Claire Presne, Philippe Grimbert, Didier Ducloux, Matthias Buchler, Moglie Le Quintrec, Nacera Ouali, Vincent Pernin, Nicolas Bouvier, Antoine Durrbach, Eric Alamartine, Christine Randoux, Virginie Besson, Marc Hazzan, Justine Pages, Sandra Colas, Marie-Liesse Piketty, Gerard Friedlander, Dominique Prie, Corinne Alberti, Eric Thervet
Summary: Vitamin D sufficiency is associated with reduced risk of complications such as fractures, diabetes, cardiovascular events, and cancers after renal transplantation. However, a study called VITALE found that high-dose cholecalciferol supplementation does not reduce extraskeletal complications in kidney transplant recipients.
AMERICAN JOURNAL OF TRANSPLANTATION
(2023)
Article
Medical Laboratory Technology
Alexandre Destere, Aurelie Premaud, Caroline Monchaud, Pierre Marquet, Jean-Baptiste Woillard
Summary: This study aimed to evaluate the relationship between cumulative tacrolimus exposure and the occurrence of new-onset diabetes mellitus (NODM). The study found that tacrolimus concentrations >15 mcg/L increase the risk of NODM.
THERAPEUTIC DRUG MONITORING
(2023)
Article
Medicine, Research & Experimental
Yannick Le Meur, Emmanuel Nowak, Benoit Barrou, Antoine Thierry, Lionel Badet, Matthias Buchler, Jean-Philippe Rerolle, Leonard Golbin, Agnes Duveau, Jacques Dantal, Pierre Merville, Nassim Kamar, Leila Demini, Franck Zal
Summary: Preventing ischemia-reperfusion injury (IRI) is crucial in kidney transplantation, especially for ECD recipients. The use of an oxygen carrier, HEMO2life (R), as an additive to preservation solution may be beneficial. The OxyOp2 trial aims to determine the efficacy of HEMO2life (R) for organ preservation in a large population of kidney grafts.
Article
Surgery
Danko Stamenic, Annick Rousseau, Marie Essig, Philippe Gatault, Mathias Buchler, Matthieu Filloux, Pierre Marquet, Aurelie Premaud
JOURNAL OF TRANSPLANTATION
(2019)